ArticleBreast cancer (Dove Medical Press)2026
Application of Shear Wave Elastography Combined with Tumor Markers in the Differential Diagnosis of Benign and Malignant Breast Masses.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the value of combined quantitative shear wave elastography (SWE) parameters and breast cancer molecular markers for the differential diagnosis of benign and malignant breast masses. Methods: This study retrospectively analyzed the clinical data of 225 patients who underwent conventional ultrasound, SWE examinations, immunohistochemical analysis, and measurement of serum tumor markers CA15-3 and CA125. Based on the pathological diagnoses, the patients were categorized into malignant (n=107) and benign (n=118) mass groups. Results: The malignant mass group exhibited significantly higher values of quantitative SWE parameters, including maximum elasticity (E max), Shell1 E max, Shell2 E max, and Shell3 E max, than the benign mass group ( Conclusion: The combined detection of quantitative SWE parameters and breast cancer molecular markers significantly enhances the accuracy of differentiating benign from malignant breast masses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.